Agger Mette Kirstine 4
4 · Trevi Therapeutics, Inc. · Filed May 13, 2019
Insider Transaction Report
Form 4
Agger Mette Kirstine
Director
Transactions
- Purchase
Common Stock
2019-05-09$10.00/sh+375,000$3,750,000→ 1,151,544 total(indirect: See Footnote) - Conversion
Common Stock
2019-05-09+776,544→ 776,544 total(indirect: See Footnote) - Conversion
Series C Preferred Stock
2019-05-09−6,849,315→ 0 total(indirect: See Footnote)→ Common Stock (776,544 underlying)
Footnotes (2)
- [F1]On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]These shares are directly held by Lundbeckfond Invest A/S. The reporting person is the Managing Partner at Lundbeckfonden Ventures, which is the General Partner of Lundbeckfond Invest A/S. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose.